Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma

This trial studies how well ultra low-dose radiation therapy works in treating patients with stage I-IV stomach mucosa-associated lymphoid tissue (MALT) lymphoma. Ultra low-dose radiation therapy may be able to kill tumor cells and shrink tumors while having fewer side effects in patients with MALT lymphoma.

  • 0 views
  • 09 Feb, 2022
  • 1 location
The Efficacy and Safety of Egg Yolk Antibody Combined With Bismuth Quadruple in the Treatment of Helicobacter Pylori

Helicobacter pylori is an important pathogenic factor for gastrointestinal diseases such as gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer.However

  • 0 views
  • 27 Jun, 2022
  • 1 location
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but do not prevent relapse later on. In addition, …

gastric malt lymphoma
tositumomab
cytopenia
measurable disease
neutrophil count
  • 10 views
  • 21 Apr, 2022
  • 10 locations
Obinutuzumab in Marginal Zone Lymphoma

For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy are widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but do not prevent relapse later on. In addition, …

gastric malt lymphoma
cancer
gilbert's syndrome
b-cell lymphoma
tositumomab
  • 25 views
  • 08 Feb, 2022
  • 14 locations
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but does not prevent relapse later on. In addition, …

  • 0 views
  • 12 Mar, 2022
  • 6 locations